Schering-Plough Corporation 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2005, for Schering-Plough Corporation. The Company is a research-based pharmaceutical firm operating in Prescription Pharmaceuticals, Consumer Health Care, and Animal Health segments. The reporting period marks the third quarter of the Company's "Turnaround" phase, driven significantly by the growth of its cholesterol franchise (VYTORIN and ZETIA) in a joint venture with Merck & Co., Inc.
Key Financial Metrics
| Metric (Nine Months Ended Sep 30, 2005) | Amount ($ Millions) | Comparison (Nine Months Ended Sep 30, 2004) |
|---|---|---|
| Net Sales | $7,184 | $6,088 (+18%) |
| Net Income | $143 | $(112) Loss |
| Net Income Available to Common Shareholders | $78 | $(124) Loss |
| Diluted EPS | $0.05 | $(0.08) |
| Operating Cash Flow | $546 | $9 |
| Equity Income (Cholesterol JV) | $605 | $249 |
| Research & Development | $1,391 | $1,201 (+16%) |
| Special Charges | $292 | $138 |
| Cash and Cash Equivalents (End of Period) | $4,194 | $4,685 |
| Total Debt (Short-term + Long-term) | $2,753 | $3,961 |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 15% in Q3 and 18% year-to-date, driven by volume growth in PEG-INTRON, REMICADE, TEMODAR, and REBETOL, as well as the inclusion of AVELOX and CIPRO sales from the Bayer agreement.
- Profitability Turnaround: The Company returned to profitability, reporting net income of $143 million for the nine months ended September 30, 2005, compared to a net loss of $112 million in the prior year. This was largely due to a $356 million increase in equity income from the cholesterol joint venture.
- Special Charges: Special charges increased significantly to $292 million (vs. $138 million in 2004). This includes a $250 million increase in litigation reserves related to the Massachusetts investigation and Average Wholesale Price (AWP) practices.
- Expense Increases: R&D expenses rose 50% in Q3 and 16% year-to-date, partially due to a $124 million charge for the acquisition of rights to develop golimumab. SG&A expenses increased due to the addition of Bayer sales representatives and promotional spending for NASONEX and ASMANEX.
- Cash Flow: Operating cash flow improved dramatically to $546 million from $9 million in the prior year, though cash balances decreased due to tax payments and dividend distributions.
Guidance, Outlook, and Risks
- Cholesterol Franchise Dependence: Management states that the Company's ability to generate profits is predominantly dependent on the performance of VYTORIN and ZETIA. Future cash flows are tied to this franchise's growth.
- Generic Competition: The Company anticipates generic competition for Pravachol and Zocor starting in 2006. There is also a risk of generic competition for Lipitor, which could impact the cholesterol market size.
- Legal and Regulatory Risks:
- Massachusetts Investigation: A $500 million reserve has been established for the U.S. Attorney's Office investigation into sales, marketing, and pricing practices. No settlement has been reached.
- Consent Decree: The Company is working to complete FDA consent decree obligations regarding manufacturing practices by December 31, 2005. Failure to meet deadlines could result in additional payments or production halts.
- AWP Litigation: Ongoing investigations and class-action lawsuits regarding Average Wholesale Price reporting could result in substantial fines and penalties.
- Liquidity: The Company is repatriating foreign earnings under the American Jobs Creation Act (AJCA) to fund U.S. operations. While current cash and investments are sufficient for the near term, the Company may need to utilize its $1.5 billion credit facility or borrowings to fund repatriations and dividends.
- Product Specifics: Sales of PEG-INTRON and REBETOL in Japan benefited from "patient warehousing" in 2005, a factor that will not recur in 2006. CLARINEX sales are expected to face pressure from the introduction of generic Allegra.
Investor Verification Checklist
- Litigation Reserve Adequacy: Verify if the $500 million reserve for the Massachusetts and AWP investigations is sufficient to cover potential settlements, fines, and penalties.
- Cholesterol JV Performance: Monitor the market share and sales growth of VYTORIN and ZETIA, as they are the primary drivers of current profitability.
- FDA Consent Decree Status: Confirm the Company's progress in meeting the December 31, 2005, deadlines for the cGMP Workplan and revalidation programs to avoid further penalties.
- Generic Impact: Assess the potential revenue erosion from the anticipated 2006 launch of generic Pravachol, Zocor, and potential Lipitor generics.
- Cash Flow Sustainability: Evaluate the sufficiency of repatriated funds under the AJCA to cover U.S. operating deficits, capital expenditures, and dividend obligations without excessive new borrowing.